Armin Graber
SVP, Head of Translational Medicine, Biomarkers and Cdx @BlossomHill Therapeutics, Inc.
Signup · Get unlimited contacts
WORK HISTORY
SVP, Head of Translational Medicine, Biomarkers and Cdx @BlossomHill Therapeutics, Inc.
Tampa, FL, US
Leading the Translational and Precision Medicine functions Clinical Biomarkers, Correlative Sciences and Companion Diagnostics at BlossomHill Therapeutics to support the global development of the clinical stage pipeline. Member of the executive leadership team at BlossomHill Therapeutics.
EDUCATION
Universität Innsbruck
Ph.D., Biostatistics and Biomedical Informatics
Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik
Priv.-Doz. (PD) ‘venia legendi’, Habilitation
Technische Universität Graz
Dipl.-Ing. (M.Eng.), Technical Mathematics and Computer Science
ABOUT ARMIN GRABER
OBJECTIVE: Improving Lives Through Precision Medicine.Experienced executive with extensive leadership to build high performing teams and organizations that positively affect patients\' lives through the development of precision medicine products.Over 35 years of experience in the biotechnology, pharmaceutical and diagnostics industries, and entrepreneurial expertise running Biotech startup companies as well as know-how in setting-up and managing research organizations, institutes, departments, and universities. Technical and scientific competence in bioinformatics, biostatistics, systems biology, biomarker discovery and qualification, assay development, clinical validation of assay, establishment of clinical utility through evidence generation, regulatory filing, commercialization, and reimbursement.A successful track record of the development and implementation of biomarker, correlative sciences, CDx and MRD strategies to support worldwide approvals of products for the treatment of hematological malignancies including Rydapt (midostaurin), Gleevec (imatinib), Tasigna (nilotinib) and Kymriah (tisagenlecleucel) and for the treatment of solid cancers such as Augtyro (repotrectinib), Tafinlar (dabrafenib) and Mekinist (trametinib), Zykadia (ceritinib) and Kisqali (ribociclib) globally. A passionate scientist with proven history of developing and operationally executing biomarker strategies in clinical study programs, leading correlative studies to find associations of biomarkers with response, explore and confirm prognostic and predictive utility of biomarkers and unearth optimal biomarker-driven (sequential) treatment decisions. Ample profile of negotiating and establishing strategic alliances with technology and distribution partners, and research collaborations. Successful execution of due diligence processes with investors and venture capital companies. Experienced in developing and executing medical affairs strategies including establishment of relationships with key opinion leaders, initiation and coordination of investigator-initiated studies, post-marketing and health economic studies, publication of scientific and clinical data, and medical support of market access and reimbursement initiatives.Well-connected within the scientific and clinical communities, as well as the biotechnology and pharmaceutical industries. More than 160 peer reviewed publications, books and patents, and proven history of writing applications for international grants with over 90% approval rate. Successful scientific management of international projects.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.